Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 3 surufatinib 2 sintilimab 2 lutetium Lu 177 dotatate 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Fluorodeoxyglucose F18 2 Everolimus 2 toripalimab 1 copper dotatate CU-64 1 Radiopharmaceuticals 1 PE regimen 1 Nivolumab 1 Interferon-alpha 1 IFL protocol 1 Gemcitabine 1 Fluorouracil 1 Etoposide 1 EC regimen 1 Copper 1 Carboplatin 1 Capecitabine 1 Bevacizumab 1 64Cu-DOTATATE 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinoma, Neuroendocrine × Radiopharmaceuticals × Clear all

NCT02236910 2024-10-15

Lu-DOTA-TATE

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Unknown

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡